<code id='8C83B50356'></code><style id='8C83B50356'></style>
    • <acronym id='8C83B50356'></acronym>
      <center id='8C83B50356'><center id='8C83B50356'><tfoot id='8C83B50356'></tfoot></center><abbr id='8C83B50356'><dir id='8C83B50356'><tfoot id='8C83B50356'></tfoot><noframes id='8C83B50356'>

    • <optgroup id='8C83B50356'><strike id='8C83B50356'><sup id='8C83B50356'></sup></strike><code id='8C83B50356'></code></optgroup>
        1. <b id='8C83B50356'><label id='8C83B50356'><select id='8C83B50356'><dt id='8C83B50356'><span id='8C83B50356'></span></dt></select></label></b><u id='8C83B50356'></u>
          <i id='8C83B50356'><strike id='8C83B50356'><tt id='8C83B50356'><pre id='8C83B50356'></pre></tt></strike></i>

          
          WSS
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion